Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs

Kyoko Ito; Keisuke Ito

doi:10.1016/j.stem.2015.07.012

Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs

Kyoko Ito, Keisuke Ito

Cell Biology

Research output: Contribution to journal › Short survey › peer-review

Abstract

Therapeutic targeting of pre-leukemic stem cells (pre-LSCs) may be a viable strategy to eradicate residual disease and prevent leukemia relapse. Now in Cell Stem Cell, Cai et al. (2015) show that loss-of-function mutations in RUNX1 reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal hematopoietic cells through increased stress resistance.

Original language	English (US)
Article number	1816
Pages (from-to)	129-131
Number of pages	3
Journal	Cell Stem Cell
Volume	17
Issue number	2
DOIs	https://doi.org/10.1016/j.stem.2015.07.012
State	Published - Aug 6 2015

ASJC Scopus subject areas

Molecular Medicine
Genetics
Cell Biology

Access to Document

10.1016/j.stem.2015.07.012

Cite this

@article{87f77c0cc7f54c82a4540bd73dd352c3,

title = "Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs",

abstract = "Therapeutic targeting of pre-leukemic stem cells (pre-LSCs) may be a viable strategy to eradicate residual disease and prevent leukemia relapse. Now in Cell Stem Cell, Cai et al. (2015) show that loss-of-function mutations in RUNX1 reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal hematopoietic cells through increased stress resistance.",

author = "Kyoko Ito and Keisuke Ito",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = aug,

day = "6",

doi = "10.1016/j.stem.2015.07.012",

language = "English (US)",

volume = "17",

pages = "129--131",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Resistance in the Ribosome

T2 - RUNX1, pre-LSCs, and HSPCs

AU - Ito, Kyoko

AU - Ito, Keisuke

PY - 2015/8/6

Y1 - 2015/8/6

N2 - Therapeutic targeting of pre-leukemic stem cells (pre-LSCs) may be a viable strategy to eradicate residual disease and prevent leukemia relapse. Now in Cell Stem Cell, Cai et al. (2015) show that loss-of-function mutations in RUNX1 reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal hematopoietic cells through increased stress resistance.

AB - Therapeutic targeting of pre-leukemic stem cells (pre-LSCs) may be a viable strategy to eradicate residual disease and prevent leukemia relapse. Now in Cell Stem Cell, Cai et al. (2015) show that loss-of-function mutations in RUNX1 reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal hematopoietic cells through increased stress resistance.

UR - http://www.scopus.com/inward/record.url?scp=84938697930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938697930&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2015.07.012

DO - 10.1016/j.stem.2015.07.012

M3 - Short survey

C2 - 26253196

AN - SCOPUS:84938697930

SN - 1934-5909

VL - 17

SP - 129

EP - 131

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 2

M1 - 1816

ER -

Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this